Press Releases

Samsung Biologics Reports Third Quarter 2022 Financial Results

Samsung Biologics a leading contract development and manufacturing organization, released today its fiscal year 2022 third-quarter financial results.

Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset

Ardigen has announced that it is supporting the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) Consortium with its technology and expertise

CD Formulation: One-Stop Pharmaceutical Formulation Solution Makes Drug Development Faster, Easier and More Cost-Effective

Andelyn Biosciences announces opening of its state-of-the-art GMP manufacturing facility to meet industry demand

Contact information Eric Blair, Chief Commercial Officer Eric.Blair@AndelynBio.com For media enquiries, please contact Imogen Quail, PR Manager, imogen.quail@ramarketingpr.com, ramarketingpr.com About Andelyn Biosciences, Inc. Andelyn is a biopharmaceutical CDMO Pioneering Solutions That Turn Hope into Reality™. Headquartered in the greater Columbus, Ohio, USA area, Andelyn’s capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP drug substance manufacturing up to 2000L, and drug product manufacturing services. Having 20+ years of experience in viral vector manufacturing, Andelyn offers its clients direct access to globally recognized thought leaders that have enabled 75+ worldwide clinical trials. With the experience gained from over 400 cGMP clinical batches and 2000+ research-grade productions, Andelyn provides its clients with end-to-end manufacturing services, advanced quality systems, full regulatory support, and supply chain vertical integration. Andelyn began operations in its state-of-the-art 200,000 sq. ft. commercial manufacturing facility in September 2022, expanding capacity across 14+ production suites for customization of new programs and tech transferred programs. Andelyn is one of a few select CDMOs that offer clinical through commercial-scale capabilities that will help fulfil Andelyn’s mission of accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients. Andelyn is owned and supported by Nationwide Children’s Hospital (NCH) and Pall-Cytiva, part of Danaher Corporation. For more information, visit: https://andelynbio.com/.

GenNext Technologies Earns the Coveted $250,000 Grand Prize Award at the 2022 BioTools Innovator Final Competition

GenNext Technologies, Inc. has announced that it received the 2022 Grand Prize Award in the BioTools Innovator competition.

EDMOND DE ROTHSCHILD EQUITY STRATEGIES IV acquires a majority stake in ONCODESIGN SERVICES

Oncodesign Services and Elyan Partners announce the completion of the acquisition of a majority stake in Oncodesign Services by ERES IV, from its main shareholders.

Inizio commits to helping limit the impact of climate change and achieving SBTi Net-Zero Standard

Inizio commits to Science Based Targets initiative

CD BioGlyco Constructures a Glycoengineered P. pastoris Expression System for Research Use

ValiRx signs IP license agreement with Kings College London to progress triple negative breast cancer treatment

Micro-Sphere Expands HPAPI Capabilities at Swiss Site

Spray drying specialist and capsule filling service contract development and manufacturing organisation (CDMO) Micro-Sphere has invested over €5 million to expand its GMP manufacturing capabilities at its facility in Monteggio, Switzerland.

Calyx IRT Delivers Flexibility to Accelerate Recruitment

Advanced IRT system enhanced with self-service functionality to quickly address trial challenges

Polio vaccination efforts must be supported by good hygiene, say experts on World Polio Day

RGHI raise awareness for good hygiene on World Polio Day 24th October

Creative BioMart Helps Brighten Up Cell Surface Display Research with Advanced Platforms

Profacgen Established a GMP Grade Stable Cell Line Development System for Research Use

INCOG BioPharma Primes Multi-Use Filling Line for Launch

About INCOG BioPharma Services Designed to deliver better. Discover the INCOG way. We designed and built INCOG BioPharma based on decades of experience with a clear purpose: to deliver better CDMO services in the injectable drug product space. The company’s service offering includes filling drug product into vials, syringes, and cartridges. INCOG BioPharma also offers support services to include formulation development, analytical development, stability testing and storage, and final inspection, labeling, packaging, and device assembly. With our dedicated team, best-in-class processes, and state-of-the-art equipment, we deliver meaningful results and stand-out customer experiences. We stand behind our motto, “in it with you,” from the moment we start work on your project. We go above and beyond to understand your requirements, meet your needs, and foster a truly collaborative partnership. For more information, visit www.incogbiopharma.com and follow us at INCOG BioPharma Services on LinkedIn.

Navignostics Selects Celegence's CAPTIS™ Technology Solution to Support IVDR Compliance

Celegence, a global provider of regulatory affairs services for the life sciences industry, is pleased to announce that Navignostics, a global developer of drug mechanisms designed to identify ideal treatments for cancer patients, has selected Celegence’s CAPTIS™ technology solution to support Performance Evaluation Reports and other PMS documentation in compliance with the In-Vitro Diagnostic Regulation (IVDR).

Ardena announces major expansion plans for Swedish site

The expansion will increase development and manufacturing for small molecules at the Södertälje facility with new equipment and increased capabilities to strengthen the firm’s existing expertise in drug substance manufacture.

A Robust Telomere Aging Clocks Platform Helps Conduct Lab-Grade Telomere Length Analysis

A robust telomere aging clocks system combined with RF, qPCR, STELA, and TESLA techniques is newly reconfigured to conduct specialized lab-grade telomere length analysis and offer comprehensive pictures of biological aging.

NDA Group is pleased to announce the expansion of the NDA Advisory Board with the appointment of Sigrid Klaar M.D., Ph.D., specialist in oncology

NDA Group has announced the expansion of the NDA Advisory Board with the appointment of Sigrid Klaar M.D., Ph.D., specialist in oncology.

Tillotts Pharma AG announces the launch of Octasa® 800mg Tablets in Canada

Tillotts Pharma AG has announced the recent launch of Octasa® 800mg (mesalazine) delayed-release tablets, as first-line treatment for moderately active ulcerative colitis (UC) in Canada.